Transient Efficacy of Tofacitinib in Alopecia Areata Universalis
April 2016
in “Case Reports in Dermatology”
TLDR Tofacitinib temporarily regrew hair in a man with alopecia, but its effects didn't last.
The document described a single case study of a 51-year-old man with alopecia areata universalis who experienced temporary hair regrowth after three months of treatment with tofacitinib, a Janus kinase inhibitor. However, the drug's efficacy diminished within a month, leading to hair loss again. This case underscores the uncertainty of long-term efficacy of Janus kinase inhibitors for treating alopecia areata and indicates the necessity for more extensive research, such as randomized clinical trials, to evaluate the potential of these medications for this condition.
View this study on karger.com →
Cited in this study
research Alopecia areata profiling shows TH1, TH2, and IL-23 cytokine activation without parallel TH17/TH22 skewing
Alopecia areata involves immune activation in the scalp, suggesting treatments targeting TH1, TH2, and IL-23 pathways.
research Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis
A man with severe hair loss and skin disease regrew his hair with no side effects after taking tofacitinib.
research Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition
Alopecia areata can be reversed by JAK inhibitors, promoting hair regrowth.
research Overview of Alopecia Areata
Alopecia areata is a genetic and immune-related hair loss condition that is often associated with other autoimmune diseases and does not typically cause permanent damage to hair follicles.
research Genetic Basis of Alopecia Areata
More research is needed to understand the genetic causes of Alopecia areata to develop better treatments.
research Alopecia Areata
Alopecia Areata is an autoimmune disease causing hair loss in patches, often starting before age 20, and while some cases recover on their own, treatments include topical corticosteroids, minoxidil, and promising new methods like IL-31 antibodies and 308-nm Excimer laser therapy.
research Interventions for alopecia areata
Current treatments for alopecia show no significant long-term benefits.
research Familial aggregation of alopecia areata
Alopecia areata, a common autoimmune hair loss condition, often runs in families.
research THE PATHOGENESIS OF ALOPECIA AREATA
Alopecia areata is likely caused by a combination of genetic factors and immune system dysfunction, and may represent different diseases with various causes.
Related
research Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A promising therapy for the treatment of alopecia areata: A case report of six patients
Tofacitinib helped regrow hair in patients with alopecia, with few side effects.